Conavi Medical Corp. Expands Its Public Offering
Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF), a pioneer in cardiovascular imaging technologies, has recently announced an exciting expansion to its public offering. This development signals a pivotal step in the company’s journey towards enhancing its innovative medical solutions aimed at aiding minimally invasive cardiovascular procedures.
Details on the Enhanced Offering
The expanded offering will now introduce common shares and pre-funded common share purchase warrants. The actual number of securities available, along with the pricing, will be negotiated based on current market conditions. This strategic adjustment allows Conavi more flexibility in responding to market interest and ensuring that they can effectively fund their ongoing projects.
Recent Adjustments to the Prospectus
On the 20th of March, Conavi filed an amended and restated preliminary short form prospectus with the relevant securities regulatory authorities. This updated document provides important information for investors and outlines the details regarding the offering, which replaces an earlier submission from January.
Focus on Technology Development
The primary aim for the funds raised through this offering is to expedite the development and pre-clinical testing of Conavi's flagship Novasight 3.0 technology. This advanced medical device reflects Conavi’s commitment to innovating in the cardiovascular sector, with an objective to submit a 510(k) clearance application to the U.S. FDA by the third quarter of the upcoming calendar year.
Strategic Partnership with Bloom Burton Securities Inc.
Conavi's offering will proceed under an agency agreement with Bloom Burton Securities Inc., recognized for its expertise in the field. This partnership will play a crucial role in navigating the complexities of the capital markets, ensuring that all transactions comply seamlessly with requisite regulations.
Closing Timeline and Regulatory Approvals
The anticipated closure date for the offering is expected to be around March 31, with flexibility based on mutual agreements between Conavi and its agent. As with any public offering, this process hinges on meeting standard closing conditions, which include obtaining necessary approvals from regulatory bodies like the TSX Venture Exchange.
Future Outlook and Market Presence
In addition to offering shares within Canada, the securities are anticipated to reach a broader audience through private placements in various international jurisdictions. This move aligns with Conavi's strategy of expanding its presence in emerging markets and solidifying its reputation as a key player in the medical technology sector.
About Novasight Hybrid™ System
The Novasight Hybrid™ System is an innovative solution that fuses intravascular ultrasound and optical coherence tomography to deliver simultaneous imaging. This patented technology is ground-breaking, enabling precision during cardiovascular interventions. The U.S. FDA has provided 510(k) clearance for clinical usage, further emphasizing the potential of this technology in improving patient outcomes.
Company Contact Information
For investor inquiries and more detailed information about Conavi Medical Corp., please reach out to:
Stefano Picone
Chief Financial Officer
(416) 483-0100
Frequently Asked Questions
What is Conavi's main focus?
Conavi Medical specializes in developing imaging technologies for minimally invasive cardiovascular procedures.
What type of offering is Conavi pursuing?
Conavi is expanding its public offering to include common shares and pre-funded common share purchase warrants.
When is the expected closure for this offering?
The anticipated closure date for the offering is around March 31, subject to regulatory and market considerations.
What will the raised funds be used for?
The funds will primarily support the development of the Novasight 3.0 technology and general corporate purposes.
Who is handling Conavi's offering?
Bloom Burton Securities Inc. is acting as the agent in this offering, facilitating the transaction and ensuring compliance with all regulations.
